ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0308

Delay in Transition from Psoriasis to Psoriatic Arthritis: A Population Based Study

Paras Karmacharya1, Kerry Wright2, Sara J. Achenbach3, Delamo Bekele2, Cynthia Crowson4, Alexis Ogdie5, Ali Duarte-Garcia2, Floranne C. Ernste3, Megha M. Tollefson1 and John Davis2, 1Mayo Clinic, Rochester MN, ROCHESTER, MN, 2Mayo Clinic, Rochester, MN, 3Mayo Clinic, Rochester, 4Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, 5University of Pennsylvania, Philadelphia, PA

Meeting: ACR Convergence 2020

Keywords: population studies, Psoriatic arthritis, Spondylarthropathies

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease which may precede, occur concurrently or after the development of psoriasis. In order to better understand the natural history of the disease we aimed to identify demographic and clinical characteristics associated with delay in transition from psoriasis to PsA.

Methods: A retrospective, population-based cohort of incident PsA patients ≥18 years of age from a geographically-defined area meeting ClASsification of Psoriatic ARthritis (CASPAR) criteria for PsA (2000-17) was identified.  Onset of psoriasis was defined as confirmatory diagnosis of psoriasis by a dermatologist or rheumatologist. Date of fulfillment of CASPAR criteria was considered as the time of onset of PsA. PsA patients were divided into two groups: patients with concurrent psoriasis and PsA (within one year of each other) and patients with psoriasis onset before PsA ( >1 year). Those patients with psoriasis development after PsA onset ( >1 year) or only family history of psoriasis were excluded. Logistic regression models adjusted for age and sex were performed to identify factors associated with delay in transition from psoriasis to PsA.

Results: There were 157 incident cases of PsA, mean age at diagnosis was 46.3 (SD=12.0) years and 46% were females. Median lag time from psoriasis onset to PsA was 263 days (interquartile range=0, 2889). 51% (n=80) of patients had concurrent psoriasis and PsA while 49% (n=77) had onset of psoriasis before PsA (Table 1). Family history of psoriasis (OR= 2.71, 95% CI 1.24 – 5.90) and psoriasis severity (OR=1.96, 95% CI 1.26 -3.06) were more likely in those who had a delay in transition from psoriasis to PsA than those who had a concomitant diagnosis (Table 2). There were no statistically significant differences in demographic features, or any of the other psoriasis or PsA related factors between the 2 groups. Similarly, no difference in radiographic outcome was noted for the 2 groups.

Conclusion: In this population-based study, approximately half of the patients had psoriasis onset before PsA, and the other half had concurrent psoriasis and PsA. Patients with a family history of psoriasis and severe psoriasis were more likely to have a delay in transition from psoriasis to PsA. Whether this difference is secondary to earlier detection of psoriasis in patients with a family history of psoriasis and severe psoriasis or a true phenotypic difference will require further studies.

Table 1. Baseline characteristics of patients with concurrent psoriasis and PsA, and psoriasis before PsA

Table 2. Logistic regression models for psoriasis before PsA adjusted for age and sex


Disclosure: P. Karmacharya, National Center for Advancing Translational Science, 2, SPARTAN (Spondyloarthritis Research and Treatment Network), 2; K. Wright, None; S. Achenbach, None; D. Bekele, None; C. Crowson, Myriad Genetics, 1, Pfizer, 1; A. Ogdie, abbvie, 1, amgen, 1, bms, 1, celgene, 1, corona, 1, lilly, 1, janssen, 1, novartis, 1, 2, novartis, 1, pfizer, 1; A. Duarte-Garcia, None; F. Ernste, None; M. Tollefson, None; J. Davis, Pfizer, 2, AbbVie, 5, 8, Sanofi-Genzyme, 5, 8.

To cite this abstract in AMA style:

Karmacharya P, Wright K, Achenbach S, Bekele D, Crowson C, Ogdie A, Duarte-Garcia A, Ernste F, Tollefson M, Davis J. Delay in Transition from Psoriasis to Psoriatic Arthritis: A Population Based Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/delay-in-transition-from-psoriasis-to-psoriatic-arthritis-a-population-based-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/delay-in-transition-from-psoriasis-to-psoriatic-arthritis-a-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology